Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RETGENTX

Financiado

Cerrado

Overcoming the challenge of large gene transfer for the therapy of inherited ret...

Overcoming the challenge of large gene transfer for the therapy of inherited retinal diseases Inherited retinal diseases (IRDs) cause blindness in over 200,000 individuals in Europe. The majority are due to mutations in genes expressed in photoreceptors (PR) in the retina. We have recently demonstrated the safety and effic... ver más

31/12/2016

FONDAZIONE TELETHO...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FONDAZIONE TELETHON ETS

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AAVEYE GENE THERAPY FOR INHERITED SEVERE PHOTORECEPTOR DISEASES 4M€ Cerrado

RETINAL-GENE-THERAPY Overcoming translational barriers to gene therapy by novel v... 100K€ Cerrado

REGENETHER Modeling and treating retinal degenerative disease 1M€ Cerrado

EYEGET Gene therapy of inherited retinal diseases 2M€ Cerrado

CNS2023-144370 Herramientas diagnósticas, pronósticas y terapéuticas 200K€ Cerrado

UshTher Clinical trial of gene therapy with dual AAV vectors for ret... 6M€ Cerrado

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inherited retinal diseases (IRDs) cause blindness in over 200,000 individuals in Europe. The majority are due to mutations in genes expressed in photoreceptors (PR) in the retina. We have recently demonstrated the safety and efficacy of gene therapy for IRDs in patients with Leber congenital amaurosis (LCA). One of the major limitations to extend this clinical success to other blinding conditions is that many are caused by mutations in genes with large coding sequences that exceed the cargo capacity of the most efficient gene transfer vector for PR, the adeno-associated virus (AAV). Conversely, vectors for large gene delivery like lentiviral (LV) or high-capacity adenoviral (HC-Ad) vectors have poor PR tropism. This project aims at overcoming the challenge of large gene delivery to the retina. We propose to either expand AAV cargo capacity or to identify/modify LV and HD-Ad vectors with improved PR transduction ability. We plan to expand AAV cargo capacity by either producing AAV vectors from single plasmid containing large genes or by generating 2-split AAV vectors each containing one of 2 halves of a large gene which is reconstituted upon AAV intermolecular concatemerization in the nucleus of target cells. In parallel, we will screen a series of existing LV pseudotypes and Ad serotypes for their ability to transduce PR. Alternatively, we propose to modify the Ad capsid or LV envelope using epitopes identified by in vivo biopanning that bind to PR and. We will compare the efficiency of the three vector platforms to transduce murine and porcine PR. The platform with highest PR transduction efficiency will then be used to correct the retinal phenotype of murine models of common severe IRDs due to mutations in large genes. Overcoming the challenge of large gene transfer will allow to cure photoreceptor-specific diseases which are currently untreatable and will provide important therapeutic tools for those diseases targeting tissues other than the retina.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores